Last reviewed · How we verify
NCT06094504
Spectral Lighting and Intestinal Failure
NA trial testing Spectral Lighting in Intestinal Failure in 32 participants. Enrolling by invitation.
15 September 2026
Quick facts
| Lead sponsor | Children's Hospital Medical Center, Cincinnati |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 32 |
| Start date | 1 March 2024 |
| Primary completion | 15 September 2026 |
| Estimated completion | 15 March 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Spectral Lighting
Conditions studied
- Intestinal Failure — all drugs for Intestinal Failure →
Sponsor
Children's Hospital Medical Center, Cincinnati
Who can join
Under 1, any sex, with Intestinal Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this exploratory n-of-1-study is to compare markers of metabolism in infants with intestinal failure between two lighting environments. Investigators are seeking to learn whether supplementing the lighting environment of infants with intestinal failure with blue and violet wavelengths of light will allow more efficient utilization of the nutrition provided to participants by influencing hormones involved in regulation of growth and development as compared to a conventional lighting environment. Pre-clinical studies suggest that violet and blue wavelengths of light are involved in molecular pathways that help regulate metabolic activity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06094504
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Intestinal Failure
Currently open trials in the same condition.
- NCT07297238 — Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration. · NA · recruiting
- NCT07414576 — AI-driven Total Parenteral Nutrition Platform · NA · recruiting
- NCT06525753 — Weaning is Winning? (WeWin Study) · recruiting
- NCT06777251 — Changing the Future of Intestinal Failure in Intestinal Chronic Inflammation (INT-FAIL) · NA · active not recruiting
- NCT06169774 — Video Training Supplementation for Patients Discharged on Home Parental Nutrition · NA · recruiting
Other Children's Hospital Medical Center, Cincinnati trials
Trials by the same sponsor.
- NCT07430332 — GLP-1 RA for Stage 1 Type 1 Diabetes · Phase 2 · not yet recruiting
- NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
- NCT07265141 — An Automated Virtual Reality Intervention to Enhance Firearm Safety Counseling in Pediatrics · NA · not yet recruiting
- NCT07217444 — Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation · NA · recruiting
- NCT07195123 — Evaluation of the SMART IBD App in Pediatric IBD · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06094504 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital Medical Center, Cincinnati
- Last refreshed: 16 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06094504.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing